関節リウマチ治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Rheumatoid Arthritis - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0645
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:1148
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥525,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Rheumatoid Arthritis – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis – Pipeline Review, H2 2019, provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape.

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 13, 2, 24, 48, 73, 10, 208, 55 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 5, 26 and 3 molecules, respectively.

Rheumatoid Arthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Rheumatoid Arthritis – Overview
Rheumatoid Arthritis – Therapeutics Development
Rheumatoid Arthritis – Therapeutics Assessment
Rheumatoid Arthritis – Companies Involved in Therapeutics Development
Rheumatoid Arthritis – Drug Profiles
Rheumatoid Arthritis – Dormant Projects
Rheumatoid Arthritis – Discontinued Products
Rheumatoid Arthritis – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Rheumatoid Arthritis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..14), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..15), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..16), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019

【掲載企業】

3SBio Inc
4D Pharma Plc
AB Science SA
AbbVie Inc
AbClon Inc
Abivax SA
Ablynx NV
ACEA Therapeutics Inc
Acelerox LLC
Aclaris Therapeutics Inc
Aevi Genomic Medicine Inc
Affilogic SAS
Agency for Science, Technology and Research
Agragen LLC
Ahead Therapeutics SL
Aibios Co Ltd
AimVion AS
Akari Therapeutics Plc
Alibion AG
Allied-Bristol Life Sciences LLC
Allosterix Ltd
Alphamab Oncology
Alpine Immune Sciences Inc
Aluda Pharmaceuticals Inc
Alvotech ehf
Amgen Inc
Amrif BV
Anew Oncology Inc
AnTolRx Inc
Apaxen
Apcegen Technologies Pvt Ltd
Apitope International NV
Applied Genetic Technologies Corp
Aprogen Inc
Archigen Biotech Ltd
arGentis Pharmaceuticals LLC
Argenx SE
Arrien Pharmaceuticals LLC
Arthrogen BV
Asahi Kasei Pharma Corp
Astellas Pharma Inc
AstraZeneca Plc
Atlanthera
Atlantic Bio Sci LLC
Auransa Inc
Aurigene Discovery Technologies Ltd
Axsome Therapeutics Inc
Axxam SpA
Bausch Health Companies Inc
Bayer AG
Baylx Inc
Beijing Eastern Biotech Co Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Beijing VDJBio Co Ltd
Bio-Cancer Treatment International Ltd
Bio-Thera Solutions Ltd
Biocad
Biocon Ltd
Biogen Inc
Bioiberica SAU
Biois Corp
BioLingus AG
BioLite Inc
Biosion Inc
Biotech Holdings
BioXpress Therapeutics SA
Biozeus Pharmaceutical SA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
BTB Pharma AB
c-a-i-r Biosciences GmbH
C4X Discovery Holdings Plc
Can-Fite BioPharma Ltd
CannBioRex Pharmaceuticals Corp
Carna Biosciences Inc
CEL-SCI Corp
Cellinbio Co Ltd
Celltrion Inc
CHA Bio & Diostech Co Ltd
CheckPoint Immunology Inc
Chipscreen Biosciences Ltd
ChironWells GmbH
Chong Kun Dang Pharmaceutical Corp
Citryll BV
CJ HealthCare Corp
Clevexel Pharma SAS
Clover Biopharmaceuticals
Coherus BioSciences Inc
Commence Bio Inc
Compugen Ltd
Cour Pharmaceuticals Development Co Inc
Crossject SA
CSL Ltd
CV6 Therapeutics (Ni) Ltd
Cyclacel Pharmaceuticals Inc
Cytocom Inc
Cyxone AB
Daewoong Pharmaceutical Co Ltd
DeMay Biotech
Denali Therapeutics Inc
Dendright Pty Ltd
Diamyd Medical AB
DiNonA Inc
Diurnal Group Plc
DM Bio Ltd
DNX Biopharmaceuticals Inc
Domainex Ltd
Dr. Reddy's Laboratories Ltd
Ducentis BioTherapeutics Ltd
Dynavax Technologies Corp
Eisai Co Ltd
Enzene Biosciences Ltd
Enzychem Lifesciences Corp
Ergon Pharmaceuticals LLC
Eternity Bioscience Inc
Eton Pharmaceuticals Inc
Evelo Biosciences Inc
Fountain Biopharma Inc
Fresenius SE & Co KGaA
Fujifilm Kyowa Kirin Biologics Co Ltd
Galapagos NV
Gene Techno Science Co Ltd
GeneFrontier Corp
Genentech Inc
Generium
GeneScience Pharmaceuticals Co Ltd
Genfit SA
Genor BioPharma Co Ltd
Genosco Inc
Genova Biotech Company Ltd
Genrix (Shanghai) Biopharmaceutical Co Ltd
Gismo Therapeutics Inc
GlaxoSmithKline Plc
GNT Biotech and Medicals Corp
GNT Pharma Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Han Wha Pharma Co Ltd
Hana Pharm Co Ltd
Hangzhou East China Pharmaceutical Group Co Ltd
Hanlim Pharm Co Ltd
Hebei Fitness Biotechnology Co Ltd
HEC Pharm Co Ltd
Hengenix Biotech Inc
HitGen LTD
Hope Biosciences LLC
HSRx Group
Huabo Biopharm Co Ltd
Hualan Biological Engineering Inc
Humabs BioMed SA
HuniLife Biotechnology Inc
Hutchison MediPharma Ltd
I-Mab Biopharma Co Ltd
iBio Inc
Ichnos Sciences Inc
ID Pharma Co Ltd
Idogen AB
IL-2Rx Inc
ImCyse SA
Immune Regulation Ltd
Immungenetics AG
ImmunoPrecise Antibodies Ltd
Immunwork Inc
Immutep Ltd
InflammatoRx inc
Innate Pharma SA
Innovent Biologics Inc
Innovimmune Biotherapeutics Inc
InSight Biopharmaceuticals Ltd
Istesso Ltd
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Jinyu Bio-technology Co Ltd
Johnson & Johnson
Jubilant Biosys Ltd
Jyant Technologies Inc
Kadmon Corp LLC
Kang Stem Biotech Co Ltd
KBP BioSciences Co Ltd
Kemmx Corp
Kezar Life Sciences Inc
KIMS Pharmaceutical Co Ltd
Kine Sciences
L2 Diagnostics LLC
Landos Biopharma Inc
Lead Pharma Holding BV
Leukosight Inc
LG Chem Ltd
LipUm AB
LISCure Biosciences Co Ltd
Livzon MabPharm Inc
Lupin Ltd
Mabion SA
Mabpharm Ltd
Mabtech Ltd
mAbxience SA
Maruho Co Ltd
Mebiopharm Co Ltd
MedAnnex Ltd
MENTRIK Biotech LLC
Merck & Co Inc
Merck KGaA
Mesoblast Ltd
MetrioPharm AG
Microbiotix Inc
Millennium Pharmaceuticals Inc
Mirae Cell Bio Co Ltd
Momenta Pharmaceuticals Inc
Moogene Medi Inc
Morphotek Inc
Mycenax Biotech Inc
MyeloRx LLC
Nascient Ltd
Navigen Inc
NeuClone Pty Ltd
Neuracle Science Co Ltd
Nichi-Iko Pharmaceutical Co Ltd
Nissan Chemical Corp
NovalGen Ltd
Novartis AG
NovImmune SA
NuBioPharma LLC
Numab Innovation AG
Octagon Therapeutics Inc
Omeros Corp
Oncodesign SA
OncoImmune Inc
Orbis Biosciences Inc
Oryn Therapeutics
OSE Immunotherapeutics
Pahan Therapeutics
Paras Biopharmaceuticals Finland Oy
Peptinov SAS
Pfizer Inc
Pharmapraxis
Philogen SpA
Promethera Biosciences SA
ProNoxis AB
Protab Ltd
Protalex Inc
Protheragen Inc
Qu Biologics Inc
R Pharm
Radikal Therapeutics Inc
Reata Pharmaceuticals Inc
ReceptoPharm Inc
RedHill Biopharma Ltd
Regen BioPharma Inc
Regenerative Arthritis & Bone Medicine Inc
Reliance Life Sciences Pvt Ltd
RemeGen Ltd
Resverlogix Corp
ReveraGen BioPharma Inc
Rhizen Pharmaceuticals SA
Ribomic Inc
Richter Gedeon Nyrt
Rigel Pharmaceuticals Inc
Rophibio Inc
ROS Therapeutics ApS
Rottapharm Biotech Srl
Saje Pharma LLC
Sareum Holdings Plc
SBI Biotech Co Ltd
Sengenics International Pte Ltd
Serene LLC
Servatus Ltd
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Biomabs Pharmaceuticals Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Pharmaceutical Co Ltd
Siam Bioscience Co Ltd
Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd
Signablok Inc
Simcere Pharmaceutical Group
Singh Biotechnology LLC
Sino Biopharmaceutical Ltd
Sinocelltech Ltd
SinoMab Bioscience Ltd
SomaLogic Inc
Splash Pharmaceuticals Inc
Suntec Medical (Taiwan) Inc
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Ribo Life Sciences Co Ltd
Suzhou Sinovent Pharmaceuticals Co Ltd
SynAct Pharma AB
Synermore Biologics Co Ltd
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Tasly Pharmaceutical Group Co Ltd
TG Therapeutics Inc
Tiziana Life Sciences Plc
Toleranzia AB
Tonix Pharmaceuticals Holding Corp
TPCera Ltd
Translational Biosciences
Tumorend LLC
Turgut Ilaclari AS
Twoxar Inc
UCB SA
United BioPharma Inc
Vaccinex Inc
Vascular Biogenics Ltd
Viela Bio Inc
Voronoi
Wuhan Institute of Biological Products Co Ltd
Wuxi Fuxin Pharmaceutical Research and Development Co Ltd
X-Rx Inc
Xalud Therapeutics Inc
Xbrane Biopharma AB
Xencor Inc
XL-protein GmbH
Y-Biologics
Yichang Humanwell Pharmaceutical Co Ltd
Yuhan Corp
Yungjin Pharm Co Ltd
Yuyu Pharma Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Zumutor Biologics Inc
ZyVersa Therapeutics Inc


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[関節リウマチ治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆